153 related articles for article (PubMed ID: 37784253)
1. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
2. The molecular aspects of chordoma.
Gulluoglu S; Turksoy O; Kuskucu A; Ture U; Bayrak OF
Neurosurg Rev; 2016 Apr; 39(2):185-96; discussion 196. PubMed ID: 26363792
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
4. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
5. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
6. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
8. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of histopathological parameters, genome-wide copy number alterations, and variants in genes involved in cell cycle regulation in chordomas of the skull base and sacrum.
Salle H; Durand S; Durand K; Bourthoumieu S; Lemnos L; Robert S; Pollet J; Passeri T; Khalil W; Froelich S; Adle-Biassette H; Labrousse F
J Neuropathol Exp Neurol; 2023 Mar; 82(4):312-323. PubMed ID: 36779322
[TBL] [Abstract][Full Text] [Related]
10. Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.
Duan W; Zhang B; Li X; Chen W; Jia S; Xin Z; Jian Q; Jian F; Chou D; Chen Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2185-2195. PubMed ID: 35084549
[TBL] [Abstract][Full Text] [Related]
11. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
12. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Optimization of Post-Treatment Surveillance for Skull Base Chordomas Based on Local and Distant Disease Progression.
Freeman JL; Kaufmann AB; Everson RG; DeMonte F; Raza SM
Oper Neurosurg (Hagerstown); 2019 Jan; 16(1):27-36. PubMed ID: 29912434
[TBL] [Abstract][Full Text] [Related]
16. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
Bai J; Shi J; Li C; Wang S; Zhang T; Hua X; Zhu B; Koka H; Wu HH; Song L; Wang D; Wang M; Zhou W; Ballew BJ; Zhu B; Hicks B; Mirabello L; Parry DM; Zhai Y; Li M; Du J; Wang J; Zhang S; Liu Q; Zhao P; Gui S; Goldstein AM; Zhang Y; Yang XR
Nat Commun; 2021 Feb; 12(1):757. PubMed ID: 33536423
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
18. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
[TBL] [Abstract][Full Text] [Related]
19. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
[TBL] [Abstract][Full Text] [Related]
20. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.
Passeri T; Gutman T; Hamza A; Adle-Biassette H; Girard E; Beaurepere R; Tariq Z; Mariani O; Dahmani A; Bourneix C; Abbritti R; Driouch K; Bohec M; Servant N; Baulande S; Decaudin D; Guichard JP; Calugaru V; Feuvret L; Guinebretière JM; Champion L; Bièche I; Froelich S; Mammar H; Masliah-Planchon J
J Neurosurg; 2023 Nov; 139(5):1270-1280. PubMed ID: 37029667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
